10 assets in Invasive Ductal Breast Carcinoma

Therapeutic assets addressing Invasive Ductal Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Letrozole Invasive Ductal Breast Carcinoma	University of Washington	P4	BBB (72)
Cis-Diamminedichloroplatinum Ii Invasive Ductal Breast Carcinoma	RenJi Hospital	P3	BB (68)
Fulvestrant Invasive Ductal Breast Carcinoma	G1 Therapeutics, Inc.	P3	BB (65)
Anastrozole Invasive Ductal Breast Carcinoma	Alliance for Clinical Trials in Oncology	P3	B (60)
Docetaxel Invasive Ductal Breast Carcinoma	RenJi Hospital	P3	B (60)
Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-Oh (Ls301) Invasive Ductal Breast Carcinoma	Integro Theranostics	P1/2	CCC (51)
68ga-dfc413 Invasive Ductal Breast Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
68Ga-NNS309 Invasive Ductal Breast Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
Alpelisib Invasive Ductal Breast Carcinoma	Vanderbilt-Ingram Cancer Center	P1	CC (43)
Huaier Granule Invasive Ductal Breast Carcinoma	Fudan University	P4	NR ()